EP Patent

EP2086972B1 — Compounds modulating c-fms and/or c-kit activity and uses therefor

Assigned to Plexxikon Inc · Expires 2013-11-20 · 12y expired

What this patent protects

Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.

USPTO Abstract

Compounds active on the receptor protein tyrosine kinases c-kit and/or c-fms are provided herewith. Also provided herewith are compositions useful for treatment of c-kit mediated diseases or conditions and/or c-fms-mediated diseases or conditions, and methods for the use thereof.

Drugs covered by this patent

Patent Metadata

Patent number
EP2086972B1
Jurisdiction
EP
Classification
Expires
2013-11-20
Drug substance claim
No
Drug product claim
No
Assignee
Plexxikon Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.